{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:54:16Z","timestamp":1773957256051,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation","doi-asserted-by":"publisher","award":["4039055"],"award-info":[{"award-number":["4039055"]}],"id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004160","name":"Mazandaran University of Medical Sciences","doi-asserted-by":"publisher","award":["20824"],"award-info":[{"award-number":["20824"]}],"id":[{"id":"10.13039\/501100004160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bbrep.2025.102440","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T12:56:13Z","timestamp":1767617773000},"page":"102440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative effects of a TLR7\/8 agonist and doxorubicin on immune checkpoint modulation and apoptosis in 4T1 breast cancer cells"],"prefix":"10.1016","volume":"45","author":[{"given":"Nazanin","family":"Joudaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0062-8792","authenticated-orcid":false,"given":"Abolghasem","family":"ajami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8813-6046","authenticated-orcid":false,"given":"Saeid","family":"Taghiloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbrep.2025.102440_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102440_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA. Cancer J. Clin."},{"issue":"10430","key":"10.1016\/j.bbrep.2025.102440_bib3","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0140-6736(23)02802-7","article-title":"Managing menopause after cancer","volume":"403","author":"Hickey","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bbrep.2025.102440_bib4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102440_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000036905","article-title":"Breast cancer: a review of risk factors and diagnosis","volume":"103","author":"Obeagu","year":"2024","journal-title":"Medicine"},{"issue":"14","key":"10.1016\/j.bbrep.2025.102440_bib6","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.3390\/ijms25147517","article-title":"Immunotherapy in breast cancer","volume":"25","author":"Dvir","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102440_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"npj Breast Cancer"},{"issue":"8","key":"10.1016\/j.bbrep.2025.102440_bib8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamaoncol.2018.7147","article-title":"Current landscape of immunotherapy in breast cancer: a review","volume":"5","author":"Adams","year":"2019","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102440_bib9","doi-asserted-by":"crossref","first-page":"394","DOI":"10.18632\/oncotarget.27877","article-title":"Tumor mutational burden as a predictor of immunotherapy response in breast cancer","volume":"12","author":"O'Meara","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrep.2025.102440_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103223","article-title":"Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials","volume":"159","author":"Tarantino","year":"2021","journal-title":"Crit. Rev. Oncol.-Hematol."},{"issue":"11","key":"10.1016\/j.bbrep.2025.102440_bib11","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/2326-6066.CIR-18-0243","article-title":"TLR stimulation during T-cell activation lowers PD-1 expression on CD8+ T cells","volume":"6","author":"Zahm","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102440_bib12","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-019-12657-w","article-title":"The TLR7\/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer","volume":"10","author":"Michaelis","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrep.2025.102440_bib13","first-page":"5","article-title":"TLR agonists for cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effects","author":"Lu","year":"2014","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102440_bib15","first-page":"786","article-title":"Expression profile of toll-like receptors in human breast cancer","volume":"21","author":"Shi","year":"2020","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102440_bib16","first-page":"6","article-title":"Treatment by PI3K\/mTOR inhibitor BEZ235 combined with TLR-7\/8 agonist interfere with immune evasion mechanisms of WEHI-3 mouse leukemia cells","volume":"19","author":"Taghiloo","year":"2022","journal-title":"Iran. J. Immunol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102440_bib17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/s12885-018-4441-3","article-title":"Mechanisms of immune evasion in breast cancer","volume":"18","author":"Bates","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbrep.2025.102440_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1302587","article-title":"Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics","volume":"15","author":"Akinsipe","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102440_bib19","article-title":"T cell exhaustion in human cancers","volume":"1879","author":"Kang","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"issue":"6","key":"10.1016\/j.bbrep.2025.102440_bib20","article-title":"CD8(+) T-cell exhaustion: impediment to triple-negative breast cancer (TNBC) immunotherapy","volume":"1879","author":"Feng","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"issue":"2","key":"10.1016\/j.bbrep.2025.102440_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4049\/immunohorizons.2000002","article-title":"TLR7 and TLR8 differentially activate the IRF and NF-\u03baB pathways in specific cell types to promote inflammation","volume":"4","author":"Bender","year":"2020","journal-title":"Immunohorizons"},{"key":"10.1016\/j.bbrep.2025.102440_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202500388","article-title":"High-integrity nanoformulation of resiquimod (R848) for dual autophagy activation and PD-L1 modulation in triple-negative breast cancer","author":"Salem","year":"2025","journal-title":"Macromol. Biosci."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102440_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51537-7","article-title":"Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination","volume":"9","author":"Gilad","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102440_bib24","first-page":"15","article-title":"Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells","volume":"44","author":"Naba","year":"2020","journal-title":"Turkish J. Biol."},{"issue":"6","key":"10.1016\/j.bbrep.2025.102440_bib25","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/cells11061042","article-title":"Extracellular vesicle-mediated IL-1 signaling in response to doxorubicin activates PD-L1 expression in osteosarcoma models","volume":"11","author":"Yati","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.bbrep.2025.102440_bib26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bbrc.2019.11.106","article-title":"Doxorubicin inhibits PD-L1 expression by enhancing TTP-mediated decay of PD-L1 mRNA in cancer cells","volume":"522","author":"Kim","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102440_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3892\/or.2020.7831","article-title":"PD-L1\/PD-1 blockade in breast cancer: the immunotherapy era","volume":"45","author":"Li","year":"2021","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102440_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2605","article-title":"Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule","volume":"12","author":"Ghebeh","year":"2010","journal-title":"Breast Cancer Res."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102440_bib29","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.3892\/mmr.2015.3885","article-title":"Toll-like receptor 7\/8 agonist, R848, exhibits antitumoral effects in a breast cancer model","volume":"12","author":"Yin","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102440_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijo.2022.5449","article-title":"The TLR7\/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer","volume":"61","author":"Zhou","year":"2022","journal-title":"Int. J. Oncol."},{"issue":"14","key":"10.1016\/j.bbrep.2025.102440_bib31","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.128633","article-title":"Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade","volume":"5","author":"Lee","year":"2020","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.bbrep.2025.102440_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004784","article-title":"Toll-like receptor 7\/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer","volume":"10","author":"Ye","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.bbrep.2025.102440_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2013","journal-title":"J. Pharm. Pharmacol."}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580825005278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580825005278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:47:38Z","timestamp":1773942458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580825005278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":32,"alternative-id":["S2405580825005278"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102440","relation":{},"ISSN":["2405-5808"],"issn-type":[{"value":"2405-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effects of a TLR7\/8 agonist and doxorubicin on immune checkpoint modulation and apoptosis in 4T1 breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102440"}}